Zimmer Biomet Leads Surgical Equipment & Consumables Stocks in Q2 Earnings Review
ByAinvest
Wednesday, Sep 17, 2025 2:10 am ET1min read
ZBH--
Zimmer Biomet, a leading provider of orthopedic and dental implants, reported earnings of $2.07 per share for the last quarter, exceeding estimates by $0.09. The company's revenue reached $2.08 billion, a 7% YoY increase, and its return on equity (ROE) was 12.76% [2]. The company's stock has been the subject of various analyst reports, with a mix of upgrades and downgrades, but overall, it remains in a "Hold" rating with an average price target of $111.00 [2].
STERIS, which specializes in sterilization and infection prevention solutions, also reported a solid quarter. The company's mission-critical role in preventing healthcare-associated infections has been instrumental in its performance. While specific earnings data for STERIS is not provided in the reference materials, its strong market position and increasing demand for its services suggest a promising outlook.
The strong performance of these companies is a positive sign for the broader surgical equipment and consumables sector, which has been resilient despite economic uncertainty and global events. As these companies continue to innovate and adapt to changing market conditions, investors can expect to see further growth and stability in this sector.
Surgical equipment and consumables - diversified stocks reported strong Q2 earnings, with revenues beating analysts' consensus estimates by 1.5%. Zimmer Biomet (NYSE:ZBH) led the pack with a 7% year-over-year revenue increase and a strong beat of analysts' full-year EPS guidance estimates. The company's stock is up 9.7% since reporting and currently trades at $100. STERIS (NYSE:STE) also reported a solid quarter, with a mission critical role in preventing healthcare-associated infections.
Diversified surgical equipment and consumables companies reported strong second-quarter (Q2) earnings, with revenues exceeding analysts' consensus estimates by 1.5%. Zimmer Biomet (NYSE: ZBH) led the pack, reporting a 7% year-over-year (YoY) revenue increase and a significant beat of analysts' full-year EPS guidance estimates. The company's stock has since surged by 9.7%, trading at $100. STERIS (NYSE: STE) also delivered a solid quarter, playing a mission-critical role in preventing healthcare-associated infections.Zimmer Biomet, a leading provider of orthopedic and dental implants, reported earnings of $2.07 per share for the last quarter, exceeding estimates by $0.09. The company's revenue reached $2.08 billion, a 7% YoY increase, and its return on equity (ROE) was 12.76% [2]. The company's stock has been the subject of various analyst reports, with a mix of upgrades and downgrades, but overall, it remains in a "Hold" rating with an average price target of $111.00 [2].
STERIS, which specializes in sterilization and infection prevention solutions, also reported a solid quarter. The company's mission-critical role in preventing healthcare-associated infections has been instrumental in its performance. While specific earnings data for STERIS is not provided in the reference materials, its strong market position and increasing demand for its services suggest a promising outlook.
The strong performance of these companies is a positive sign for the broader surgical equipment and consumables sector, which has been resilient despite economic uncertainty and global events. As these companies continue to innovate and adapt to changing market conditions, investors can expect to see further growth and stability in this sector.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet